Form D · Pharmaceuticals

Enliven Therapeutics, Inc.

Boulder, CO · CIK 0001672619

Offering snapshot reported Apr 3, 2024 · SEC filing

Reported sold
$90M
Offering amount: $90M
Investors reported
20
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 21, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 3, 2024Initial$90,001,086No comparison20SEC filing
Mar 29, 2019Initial$44,099,096No comparison11SEC filing
Apr 21, 2016Initial$6,000,000No comparison7SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-509579

Source: Form D, filed Apr 3, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Christoph M. Adams Executive
Mette Kirstine Agger Director
Rahul Ballal Director
Jake Bauer Director
David Bonita Director
Mark Chin Director
Helen Collins Executive
Barbara Dalton Director
Mika Derynck Director
Carl Goldfischer Director
Rishi Gupta Director
Richard Heyman Director
Benjamin Hohl Executive
Robert Hopfner Director
Samuel Kintz Director, Executive
Joseph P. Lyssikatos Director, Executive
James G. Mc Arthur Director
David Mott Director
Sara Nayeem Director
Anish Patel Executive
Andrew Phillips Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
6200 Lookout Road
Boulder, CO, 80301